drugset / Trial / NCT04387734
Effects of Ocrevus in Relapsing Multiple Sclerosis
Phase 4
Active not recruiting
60 enrolled
Georgia State University
Multiple Sclerosis Center of Atlanta · collab
Non-randomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to test if people with relapsing multiple sclerosis (RMS) can improve ambulatory functions after one-year treatment with Ocrevus in comparison with other Disease Modifying Treatments (DMT). Sixty qualified individuals with RMS will be evenly assigned into two groups: Ocrevus and other DMT. Each group will receive the respective treatment following the FDA regulations over the one-year course. Their ambulatory functions will be assessed five times three months apart. In addition, they will receive brain MRI scans three times six months apart. Their ambulatory functions and MRI measurements will be compared between groups over time to fulfill the purposes of this study.
Timeline
- Start
- 2021-02-05
- Primary completion
- 2025-02-17
- Completion
- 2026-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ocrelizumab | Monoclonal antibody | — | — |